Dr. Anthony B. Post, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 89
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
OH license 35-054897
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 89
- Services billed
- 160
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 99 | 69 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 76 | 27 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 19 | 17 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 17 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tacrolimus Other prescribers in Cleveland, OH | 138 |
| Ursodiol Other prescribers in Cleveland, OH | 88 |
| Vemlidy (tenofovir alafenamide) | 67 |
| Spironolactone Other prescribers in Cleveland, OH | 66 |
| Xifaxan (rifaximin) Other prescribers in Cleveland, OH | 62 |
| Prednisone Other prescribers in Cleveland, OH | 61 |
| Furosemide Other prescribers in Cleveland, OH | 47 |
| Pantoprazole Sodium Other prescribers in Cleveland, OH | 39 |
| Carvedilol Other prescribers in Cleveland, OH | 37 |
| Amlodipine Besylate Other prescribers in Cleveland, OH | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $86.01 in total to this clinician.
| AbbVie Inc. | $30.88 |
|---|---|
| Gilead Sciences, Inc. | $27.76 |
| Madrigal Pharmaceuticals | $27.37 |
| Food and Beverage | $86.01 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $34,152 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis
Intercept Pharmaceuticals, Inc. - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Ipsen Bioscience Inc. · Active, not recruiting · NCT04526665 - Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
Intercept Pharmaceuticals, Inc. - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Gilead Sciences, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.